FAQ - Bulk Billed MBS patient COVID-19 Vaccine Suitability Assessment Service

Information on the MBS COVID-19 Vaccine Suitability Assessment Service

Page last updated: 12 November 2021

The Australian Government is committed to offering every person in Australia access to safe and effective COVID-19 vaccines at no cost. Providers are not to charge out of pocket expenses to Medicare eligible or ineligible patients.

From March 2021, 16 new MBS items (MBS items 93624 to 93656) inclusive were introduced to enable general practitioners (GPs) and Other Medical Practitioners (OMPs) and suitably qualified health professionals to assess patients for their suitability to receive a COVID-19 vaccine.

The MBS COVID-19 vaccine suitability assessment service is free to Medicare eligible patients and the MBS items must be bulk billed.

On 14 June 2021, the Australian Government introduced MBS item 90005 to provide a call-out or flag-fall fee for GPs and OMPs who conduct a COVID-19 vaccine suitability assessment service in a residential aged care facility (RACF), a residential disability facility setting or at a patient’s place of residence.MBS item 90005 provides a flag-fall fee for an initial attendance at a RACF, residential disability facility setting or a patient’s place of residence, on one occasion, applicable only to the first patient seen. The item must be billed in association with a COVID-19 vaccine suitability assessment service.

From 18 June 2021, the Government introduced two new MBS items (10660 and 10661) to support GPs and OMPs to provide in-depth clinical assessments of patients regarding their individual health risks and benefits associated with receiving a COVID-19 vaccine.

MBS items 10660 and 10661 may only be claimed where a General Practitioner (GP) or Other Medical Practitioner (OMP) attends to a patient in person for more than 10 minutes, and must be provided in conjunction with a relevant MBS COVID-19 vaccine suitability assessment item.

Consistent with the other MBS vaccine suitability assessment items, items 10660 and 10661 must be bulk-billed.

From 11 October 2021, the Government announced that individuals who are severely immunocompromised should receive a third dose of COVID-19 vaccine. Assessment of suitability for these third doses are eligible for MBS reimbursement with the same rules as suitability assessments for second doses. The same suitability assessment for the second dose MBS items are used, including when a medical practitioner performs a suitability assessment for a patient and determines they are not suitable for a third vaccination dose.

In line with the most recent advice of the Australian Technical Advisory Group on Immunisation (ATAGI), where a minimum of 6 months has passed since a person’s second dose of COVID-19 vaccine, they may seek a booster dose. Medical practitioners providing booster dose vaccination services should use the appropriate suitability assessment for the second dose MBS item to assess the patient’s suitability for the service and to bill Medicare.

ATAGI has also advised that it is no longer necessary to wait two weeks between a COVID-19 vaccination and an influenza vaccination. These services may now be provided during the same attendance.

Important note: while medical practitioners are not required to bulk-bill patients receiving influenza vaccinations a patient who also receives a COVID-19 booster vaccination as part of the same occasion of care must be bulk-billed for the COVID-19 vaccine suitability assessment component of the overall service.

To avoid doubt, no fee can be charged to a patient (Medicare eligible or Medicare ineligible) for any reason under this program if receiving the COVID-19 vaccine is contingent on that fee or service.


Last updated 11 November 2021
PDF version FAQ-COVID-19 Vaccine Support Items including booster doses and co-administered vaccines (PDF 527 KB)
Word version FAQ-COVID-19 Vaccine Support Items including booster doses and co-administered vaccines (Word 438 KB)


In this section